BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 8:55:00 PM | Browse: 1001 | Download: 888
Publication Name World Journal of Gastroenterology
Manuscript ID 2713
Country China
Received
2013-03-11 08:41
Peer-Review Started
2013-03-12 12:09
To Make the First Decision
2013-04-16 08:57
Return for Revision
2013-04-17 12:54
Revised
2013-04-24 16:01
Second Decision
2013-05-09 13:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-05-10 10:54
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-06-03 21:54
Typeset the Manuscript
2013-06-27 16:36
Publish the Manuscript Online
2013-06-28 23:55
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
Manuscript Source Invited Manuscript
All Author List Jian-Ming Xu, Yan Wang, Fei-Jiao Ge, Li Lin, Ze-Yuan Liu and Manish R Sharma
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation Project 30971579
Capital Development Foundation 2007-2029
Corresponding Author Jian-Ming Xu, MD, Department of GI Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, No. 8 Dongda Avenue, Fengtai District, Beijing 100071, China. jmxu2003@yahoo.com
Key Words Irinotecan; Toxicity; UGT1A1*28; UGT1A1*6; Polymorphism
Core Tip This is the first reported case. This patient with heterozygous UGT1A1*28 and UGT1A1*6 polymorphisms experienced two dose reductions of irinotecan due to severe toxicity according to pharmacokinetic analyses of SN-38 and SN-38 glucuronide levels. It seems that this patient benefited from a longer treatment duration, suggesting that irinotecan dose individualization for mutant metastatic colorectal cancer patients with heterozygous UGT1A1*28 or UGT1A1*6 polymorphisms may be warranted.
Publish Date 2013-06-28 23:55
Citation Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR. Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms. World J Gastroenterol 2013; 19(24): 3899-3903
URL http://www.wjgnet.com/1007-9327/full/v19/i24/3899.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i24.3899
Full Article (PDF) WJG-19-3899.pdf
Manuscript File 2713-Review.doc
Answering Reviewers 2713-Answering reviewers.pdf
Copyright License Agreement 2713-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 2713-Language certificate.pdf
Peer-review Report 2713-Peer reviews.pdf
Scientific Editor Work List 2713-Scientific editor work list.doc